Cytiva's latest project to open in Switzerland at the end of the month
Global life sciences company Cytiva hasn’t been shy about its plans to pump money into expanding global operations. Tuesday, it announced that it would open the doors at its latest big manufacturing site in Europe in a move that will quadruple its manufacturing capacity.
Cytiva’s new site in Grens, Switzerland will house its Center of Excellence for cell and gene therapies and will be used in regulatory-approved therapies and clinical trials.
The nearly 80,000 square-feet site will be open for business on May 31. The site will manufacture single-use kits for Sepax and Sefia cell processing systems, and consumables for Xuri cell expansion systems. It will also serve as a home base for European customers and their training programs. 250 employees are set to work here at the start. A groundbreaking ceremony will be held on May 31 to mark the event.
“Cell and gene therapies have the potential to change the global healthcare landscape,” said Catarina Flyborg VP of C&G Therapy at Cytiva. “Our new facility in Grens will enable us to meet global demand for our products, while working with our customers to meet their immediate training and development needs. This facility brings us another step closer to our vision where access to life-changing therapies transforms human health.”
The already-existing site in Eysins will keep operating through the end of next year, while full production is transferred to the newest site in Grens. The new site has been built to Swiss Minergie standards, and is powered by 100% renewable electricity and has mounted solar panels on the roof. The company said that the dynamic cleanroom controls could reduce the amount of energy it uses by 60%.
“Cytiva is one of the world’s leading life sciences companies,” said Philippe Leuba, Switzerland’s Minister of Economic Affairs, in a statement. “Its decision to expand operations in Switzerland is a testament to our innovation ecosystem that has played a significant role in developing some of the most advanced therapeutics.”
Cytiva has pledged $1.5 billion to expand its manufacturing operations around the world, as it looks to shift the focus to in-region, for-region manufacturing. In March, it opened a new 118,400 square-foot site in Cardiff, Wales that’s focused on manufacturing single-use bioprocessing tech. That site will serve customers around the world, but provide customers in the UK and Europe with a closer operation to work with. That site will focus on Cytiva’s cancer, autoimmune and rare disease drug clients, as well as Covid-19 vaccines.
It also has pledged $52.5 million in South Korea for the manufacturing of cell culture fluid, which at the time, was in very short supply. It expanded two locations in central Massachusetts in 2020 with the addition of 130 new jobs in Westborough and an upgrade at its Shrewsbury site too.